Completed PHASE4 INTERVENTIONAL 2-arm NCT01271244

Effects of Escitalopram on Autonomic Reactivity in Post Traumatic Stress Disorder

Effects of Escitalopram on Autonomic Reactivity in Post Traumatic Stress Disorder Among Veterans of Operation Enduring Freedom and Iraqi Freedom (OEF/OIF)

Sponsor: Forest Laboratories

Conditions PTSD

Interventions Escitalopram

Updated 10 times since 2017 Last updated: Apr 30, 2019 Started: Jun 30, 2008 Primary completion: Jun 30, 2013 Completion: Jun 30, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates PTSD and is currently completed. Forest Laboratories leads this study, which shows 10 recorded versions since 2008 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

10 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2023 — Jul 2024 [monthly]

Completed PHASE4
Dec 2022 — Jan 2023 [monthly]

Completed PHASE4
Dec 2021 — Dec 2022 [monthly]

Completed PHASE4

▶ Show 5 earlier versions

Jan 2021 — Dec 2021 [monthly]

Completed PHASE4
Jun 2019 — Jan 2021 [monthly]

Completed PHASE4
Jun 2018 — Jun 2019 [monthly]

Completed PHASE4
Feb 2017 — Jun 2018 [monthly]

Completed PHASE4
Jan 2017 — Feb 2017 [monthly]

Completed PHASE4

First recorded

Jun 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Forest Laboratories
VA Nebraska Western Iowa Health Care System

Data source: VA Nebraska Western Iowa Health Care System

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Omaha, United States